Literature DB >> 9192149

Prevalence of perceived symptoms of dry mouth in an adult Swedish population--relation to age, sex and pharmacotherapy.

T Nederfors1, R Isaksson, H Mörnstad, C Dahlöf.   

Abstract

The aim of the study was to evaluate the prevalence of subjective perception of dry mouth in an adult population and to determine the prevalence of pharmacotherapy in this population. An additional aim was to assess a possible co-morbidity between symptoms of dry mouth and continuing pharmacotherapy. Four-thousand-two-hundred persons were selected at random from the national census register of the adult population of the southern part of the province of Halland, Sweden. The sample was stratified according to age and sex, and 300 men and an equal number of women aged 20, 30, 40, 50, 60, 70 and 80, were included. A newly developed questionnaire was mailed to each individual. In addition to questions about subjective perception of dry mouth, the subjects were asked to report on present diseases and continuing pharmacotherapy. Three-thousand-three-hundred and thirteen (80.5%) evaluable questionnaires were returned. The estimated prevalence of xerostomia in the population was 21.3% and 27.3% for men and women, respectively. This difference between the sexes was statistically significant. In non-medicated subjects, women tended to report a higher prevalence of xerostomia compared with men, 18.8% vs. 14.6%, and also among medicated subjects the estimated prevalence of dry mouth was higher for women than for men, 32.5% vs. 28.4%. There was a strong association between xerostomia and increasing age and also between xerostomia and continuing pharmacotherapy. The average prevalence of dry mouth among medicated and non-medicated subjects was 32.1% and 16.9%, respectively, the difference being statistically significant. There was also a strong association between xerostomia and the number of medications. In a logistic regression, the probability of reporting mouth dryness was significantly greater in older subjects and in women, and the probability increased with the number of medications taken. In conclusion, this epidemiological survey of an adult population has demonstrated that women, independent of age, do report a higher prevalence of xerostomia than men and that the symptom of dry mouth is strongly associated with age and pharmacotherapy. It is, however, not possible to discriminate between disease and pharmacotherapy as causal factors.

Entities:  

Mesh:

Year:  1997        PMID: 9192149     DOI: 10.1111/j.1600-0528.1997.tb00928.x

Source DB:  PubMed          Journal:  Community Dent Oral Epidemiol        ISSN: 0301-5661            Impact factor:   3.383


  43 in total

Review 1.  World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment.

Authors:  Alessandro Villa; Andy Wolff; Doron Aframian; Arjan Vissink; Jörgen Ekström; Gordon Proctor; Richard McGowan; Nagamani Narayana; Ardita Aliko; Ying Wai Sia; Revan Kumar Joshi; Siri Beier Jensen; Alexander Ross Kerr; Colin Dawes; Anne Marie Lynge Pedersen
Journal:  Clin Oral Investig       Date:  2015-05-22       Impact factor: 3.573

Review 2.  The Differential Diagnosis of Dry Eyes, Dry Mouth, and Parotidomegaly: A Comprehensive Review.

Authors:  Divi Cornec; Alain Saraux; Sandrine Jousse-Joulin; Jacques-Olivier Pers; Sylvie Boisramé-Gastrin; Yves Renaudineau; Yves Gauvin; Anne-Marie Roguedas-Contios; Steeve Genestet; Myriam Chastaing; Béatrice Cochener; Valérie Devauchelle-Pensec
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 8.667

3.  Xerostomia and medications among 32-year-olds.

Authors:  William Murray Thomson; Richie Poulton; Jonathan Mark Broadbent; Shaima Al-Kubaisy
Journal:  Acta Odontol Scand       Date:  2006-08       Impact factor: 2.331

Review 4.  Xerostomia and hyposalivation: causes, consequences and treatment in the elderly.

Authors:  T O Närhi; J H Meurman; A Ainamo
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

Review 5.  Prevention of erosive tooth wear: targeting nutritional and patient-related risks factors.

Authors:  M A R Buzalaf; A C Magalhães; D Rios
Journal:  Br Dent J       Date:  2018-03-02       Impact factor: 1.626

Review 6.  A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life.

Authors:  S B Jensen; A M L Pedersen; A Vissink; E Andersen; C G Brown; A N Davies; J Dutilh; J S Fulton; L Jankovic; N N F Lopes; A L S Mello; L V Muniz; C A Murdoch-Kinch; R G Nair; J J Napeñas; A Nogueira-Rodrigues; D Saunders; B Stirling; I von Bültzingslöwen; D S Weikel; L S Elting; F K L Spijkervet; M T Brennan
Journal:  Support Care Cancer       Date:  2010-03-17       Impact factor: 3.603

7.  Relation between Clinical Oral Dryness Score and Denture Satisfaction among Patients' in a Tertiary Care Centre, India.

Authors:  Radhika Doppalapudi; Sudhakar Vundavalli; A Kaleswara Rao; Sriharsha Babu Vadapalli; Duggineni Chalapathi Rao; Ayesha Thabusum
Journal:  J Clin Diagn Res       Date:  2017-05-01

8.  Efficacy of GUM® Hydral versus Biotène® Oralbalance mouthwashes plus gels on symptoms of medication-induced xerostomia: a randomized, double-blind, crossover study.

Authors:  Anna Greta Barbe; Yasmin Schmidt-Park; Stefanie Hamacher; Sonja Henny Maria Derman; Michael Johannes Noack
Journal:  Clin Oral Investig       Date:  2017-03-28       Impact factor: 3.573

9.  Activity of rheumatoid arthritis correlates with oral inflammatory burden.

Authors:  Leena Äyräväinen; Anna Maria Heikkinen; Antti Kuuliala; Kirsi Ahola; Riitta Koivuniemi; Jaakko Peltola; Anni Suomalainen; Eeva Moilanen; Mari Hämäläinen; Leena Laasonen; Jukka H Meurman; Marjatta Leirisalo-Repo
Journal:  Rheumatol Int       Date:  2018-07-24       Impact factor: 2.631

10.  [Xerostomia and its impact on oral health-related quality of life].

Authors:  Gianna Herrmann; Karolina Müller; Michael Behr; Sebastian Hahnel
Journal:  Z Gerontol Geriatr       Date:  2015-10-27       Impact factor: 1.281

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.